Unlock the editor’s summary for free
Roula Khalaf, editor of the FT, selects her favorite stories in this weekly newsletter.
The Danish pharmaceutical group Novo Nordisk has reduced sales sales and forecasts after drug replicas reached their successful GLP-1 obesity and Wogovy and Ozempic diabetes medications in the United States.
The company exceeded the operational gains forecasts for the first quarter of the year, but said it had been affected by compound preparations made by pharmacies using active drug ingredients.
“In the first quarter of 2025, we offered a sales growth of 18 percent and continue to expand the scope of our innovative treatments GLP-1,” said Lars Fruergaard Jørgensen, president and executive director. “However, we have reduced our full-year perspective due to the most slow LPG-1 penetration, which is affected by the rapid expansion of composition in the United States.”
Novo also said that their US operations would no longer have to meet the company’s global gender objectives, since the administration of President Donald Trump applies pressure to eliminate diversity initiatives.
It is now expected that the growth of sales for this year will be from 13 to 21 percent to constant exchange rates, compared to the previous orientation or from 16 to 24 percent. The growth of operational gains is forecast from 16 to 24 percent, compared to an earlier range or 19 to 27 percent.
Sales increased 18 percent year -on -year to DKR78.1bn ($ 11.9 billion) at constant exchange rates in the first quarter. Operating profits rose 20 percent to DKR38.8bn, exceeding the forecasts of consensus analysts.
Novo shares increased more than 5 percent in morning negotiation.
The compound was in the United States after the food and medication administration regulator declared official shortage in 2022 or Wagovy, Ozempic and Zepbound, which is made by Novo Eli Lilly’s rival. Patients have a leg capable of buying products composed of only $ 199 per months. The list prices of brand medications, charged to people without insurance, are $ 1,000 or more.
The FDA has now said that the shortage is over, which means that pharmacies should stop selling versions composed of Novo drugs before May 22.
Novo said he waits “a step forward in the business that used to go to the compounds” in the second half of the year, according to financial director Karsten Mock Knudsen. Another potential impulse for Wegovy includes selling it to discount rates at the CVS chain of the pharmacy and through Telesalud companies. Novo also plans to accelerate its international expansion or their partner outside the United States, Knudsen said.
“We have currently launched in around 25 markets and we see an accelerated launching schedule after the increase in supplies,” he said.
In a statement together with its results, the drug manufacturer said: “While Novo Nordisk maintains our global asmiring of a minimum representation of 45 per center for each genre at the end of 2025, Novo Nordisk operations in the US. Uu. Thei Globate, Theis Globate, Theis Globate, said this globe.
There none has yet been announced, the pharmaceutical industry will have to deal with US tariffs on pharmaceutical imports. Tariffs “can have a negative impact on Novo Nordisk and our industry,” said the company on Wednesday.
Novo has a significant production capacity already in the US. And exports more in the country than imports, said Jørgensen. He has announced more than $ 24 billion of investments in the United States during the last decade.
Novo was showing “encouraging” of “fighting” in front of the inverters worried that he was losing land before Lilly, said Emily Field, an analyst at Barclays.
“The results and the guide cut are mostly in the field of what people had their legs waiting,” Field said. “What people are really due to know about them is how safe are that volumes will increase in the second half, because it is a volume play.”
Novo has also faced a scrutiny of investors about their medications planned by obesity and successor diabetes, after two series of results of worse essays than expected for its product cagrisema.
]